TD Asset Management
ELVN icon

TD Asset Management’s Enliven Therapeutics ELVN Stock Holding History

TD Asset Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.57M Buy
109,738
+101,138
+1,176% +$4.29M ﹤0.01% 786
2026
Q1 		$337K Buy
+8,600
New +$238K ﹤0.01% 1194
2025
Q4 		– Sell
-27,518
Closed -$563K – 1252
2025
Q3 		$563K Sell
27,518
-39,388
-59% -$794K ﹤0.01% 1162
2025
Q2 		$1.34M Buy
+66,906
New +$1.27M ﹤0.01% 1022

Other funds holding ELVN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TD Asset Management's ELVN Position: Q2 2026 in Review

TD Asset Management increased its Enliven Therapeutics (ELVN) stake by 1,176% in Q2 2026, buying an estimated $4.29M and bringing the position to 109,738 shares worth $5.57M. The position accounts for ﹤0.01% of the portfolio, ranked #786.

TD Asset Management first reported a position in ELVN in Q2 2025 and has held it in 4 quarters since. 113 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • TD Asset Management held 109,738 shares of Enliven Therapeutics worth $5.57M as of Q2 2026.
  • TD Asset Management bought 101,138 Enliven Therapeutics shares in Q2 2026, an estimated $4.29M.
  • Enliven Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #786 holding.
  • TD Asset Management first reported a position in Enliven Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 113 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.